

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/871,367	05/31/2001	Katrin Kriwet	4-30724A	1754	
1095	7590 09/24/2002				
	THOMAS HOXIE			EXAMINER	
NOVARTIS CORPORATION PATENT AND TRADEMARK DEPT			KIM, VICKIE Y		
564 MORRIS					
SUMMIT, NJ 079011027			ART UNIT	PAPER NUMBER	
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			1614		
			DATE MAILED: 09/24/2002	1/	

Please find below and/or attached an Office communication concerning this application or proceeding.

i¶,		Application No.	Applicant(s)
Advisory Action		09/871,367	MURASHIMA, ATSUSHI
		Examin r	Art Unit
		Vickie Kim	1614
Th MA	ILING DATE of this communication appe	ars on the cover sheet with the o	correspondence address
final rejection und condition for allow	FAILS TO PLACE THIS APPL action by the applicant is required to av- ler 37 CFR 1.113 may only be either: (1) vance; (2) a timely filed Notice of Appeal E) in compliance with 37 CFR 1.114.) a timely filed amendment which	ation. A proper reply to a
_	PERIOD FOR RE	PLY [check either a) or b)]	
b) The period no event, I ONLY CHI 706.07(f). Extensions of tim fee have been filed is fee under 37 CFR 1.1 (2) as set forth in (b) a	d for reply expires 6_months from the mailing date of this A for reply expires on: (1) the mailing date of this A nowever, will the statutory period for reply expire I ECK THIS BOX WHEN THE FIRST REPLY WAS the may be obtained under 37 CFR 1.136(a). The the date for purposes of determining the period of 7(a) is calculated from: (1) the expiration date of above, if checked. Any reply received by the Office any earned patent term adjustment. See 37 C	Advisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing FILED WITHIN TWO MONTHS OF The date on which the petition under 37 CF of extension and the corresponding amount the shortened statutory period for reply the later than three months after the mail	g date of the final rejection. HE FINAL REJECTION. See MPEP R 1.136(a) and the appropriate extension unt of the fee. The appropriate extension originally set in the final Office action; or
37 CFR 1.1	Appeal was filed on Appellant's 92(a), or any extension thereof (37 CFF ed amendment(s) will not be entered be	R 1.191(d)), to avoid dismissal o	
,	aise new issues that would require further		see NOTE below):
	aise the issue of new matter (see Note b	·	see No 12 Below),
(c) ☐ they a	re not deemed to place the application in for appeal; and/or	•	rially reducing or simplifying the
(d) 🗌 they p	resent additional claims without cancell	ng a corresponding number of fi	nally rejected claims.
NOTE	: See Continuation Sheet.		
3.☐ Applicant's	reply has overcome the following rejecti	on(s):	
	osed or amended claim(s) would the non-allowable claim(s).	be allowable if submitted in a se	eparate, timely filed amendment
	ffidavit, b) exhibit, or c) request for in condition for allowance because:		dered but does NOT place the
	it or exhibit will NOT be considered beca he Examiner in the final rejection.	ause it is not directed SOLELY to	o issues which were newly
	es of Appeal, the proposed amendment n of how the new or amended claims wo		
The status	of the claim(s) is (or will be) as follows:		
Claim(s) a	llowed:		
Claim(s) o	bjected to:		
Claim(s) re	ejected: <u>14-41</u> .		
Claim(s) w	ithdrawn from consideration:		
8. The propos	ed drawing correction filed on is	a)☐ approved or b)☐ disapp	roved by-the Examiner.
9. Note the at 10. Other:	tached Information Disclosure Statemer	it(s)(PTO-1449) Paper No(s)	William Jame
			WILLIAM H. A. JARVIS PRIMARY EXAMINER
			ARTUNIT 1614

U.S. Patent and Trademark Office

Continuation Sheet (PTO-303)

Application No. 09/871,368



Continuation of 2. NOTE: Newly proposed amendment changed the scope of the claims from carrier system composition to a topical pharmaceutical composition containing a drug(i.e. ascomycin). For instantce, carrier sustem composition requires (i) means to retain water, and (ii)means to hinder waster whereas the proposed claims requires a pharmaceutical agent, (i) means to retain water (ii) means to hinder water.